Skip to main content
Home
  • Company
    • History
    • Leadership
    • Clients and Collaborators
    • By the Numbers
  • Capabilities
    • Emmes - CRO
      • Specialties
        • Vaccines & Infectious Diseases
        • Ophthalmology
        • Clinical Neuroscience
        • Rare Disease
        • Cell & Gene Therapy
        • Government
      • Additional Specialties
        • Hematology
        • Oncology
        • Maternal & Child Health
        • Medical Devices
      • Clinical Services
        • Biostatistics
        • Clinical Data Management
        • Clinical Research Services
        • Clinical Trial Management
        • Global Regulatory Affairs
        • Pharmacovigilance & Medical Monitoring
    • Veridix - Tech & AI
      • eClinical Platform
        • EDC
        • Decentralized Clinical Trials
        • Health Navigator
        • RTSM
        • eCOA / ePRO
      • AI Agents
        • Biostats and Analysis Agent
        • Data Management Agent
        • Document Authoring
      • GlobalTrace
      • Analytics & Reporting
        • Clinical Pipelines
        • VERA
  • Resources
    • Newsroom
    • Blog
  • Careers
  • Contact
    • Locations
    • Contact Us

Breadcrumb

  1. Emmes Group

Monitoring Serious Adverse Events in the Sierra Leone Trial to Introduce a Vaccine Against Ebola.

Go back to Resources

Monitoring Serious Adverse Events in the Sierra Leone Trial to Introduce a Vaccine Against Ebola.

Authors:

Secondary:

Volume:

Pagination:

Issue:

PMID:

DOI:

Keywords:

Abstract:

Go back to Resources

Health Conditions in an Adult Population in Sierra Leone: Data Reported From the Sierra Leone Trial to Introduce a Vaccine Against Ebola (STRIVE).

Go back to Resources

Health Conditions in an Adult Population in Sierra Leone: Data Reported From the Sierra Leone Trial to Introduce a Vaccine Against Ebola (STRIVE).

Authors:

Secondary:

Volume:

Pagination:

Issue:

PMID:

DOI:

Keywords:

Abstract:

Go back to Resources

Genetic variants at the 16p13 locus confer risk for eosinophilic esophagitis.

Go back to Resources

Genetic variants at the 16p13 locus confer risk for eosinophilic esophagitis.

Authors:

Secondary:

Volume:

Pagination:

Issue:

PMID:

DOI:

Keywords:

Abstract:

Go back to Resources

Early-life gut microbiome and egg allergy.

Go back to Resources

Early-life gut microbiome and egg allergy.

Authors:

Secondary:

Volume:

Pagination:

Issue:

PMID:

DOI:

Keywords:

Abstract:

Go back to Resources

DNA vaccine priming for seasonal influenza vaccine in children and adolescents 6 to 17 years of age: A phase 1 randomized clinical trial.

Go back to Resources

DNA vaccine priming for seasonal influenza vaccine in children and adolescents 6 to 17 years of age: A phase 1 randomized clinical trial.

Authors:

Secondary:

Volume:

Pagination:

Issue:

PMID:

DOI:

Keywords:

Abstract:

Go back to Resources

Data sharing platforms for de-identified data from human clinical trials.

Go back to Resources

Data sharing platforms for de-identified data from human clinical trials.

Authors:

Secondary:

Volume:

Pagination:

Issue:

PMID:

DOI:

Keywords:

Abstract:

Go back to Resources

Clinical Surveillance and Evaluation of Suspected Ebola Cases in a Vaccine Trial During an Ebola Epidemic: The Sierra Leone Trial to Introduce a Vaccine Against Ebola.

Go back to Resources

Clinical Surveillance and Evaluation of Suspected Ebola Cases in a Vaccine Trial During an Ebola Epidemic: The Sierra Leone Trial to Introduce a Vaccine Against Ebola.

Authors:

Secondary:

Volume:

Pagination:

Issue:

PMID:

DOI:

Keywords:

Abstract:

Go back to Resources

Chloroquine as weekly chemoprophylaxis or intermittent treatment to prevent malaria in pregnancy in Malawi: a randomised controlled trial.

Go back to Resources

Chloroquine as weekly chemoprophylaxis or intermittent treatment to prevent malaria in pregnancy in Malawi: a randomised controlled trial.

Authors:

Secondary:

Volume:

Pagination:

Issue:

PMID:

DOI:

Keywords:

Abstract:

Go back to Resources

Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802.

Go back to Resources

Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802.

Authors:

Secondary:

Volume:

Pagination:

Issue:

PMID:

DOI:

Keywords:

Abstract:

Go back to Resources

A Phase I trial to evaluate the safety and immunogenicity of WRSs2 and WRSs3; two live oral candidate vaccines against Shigella sonnei.

Go back to Resources

A Phase I trial to evaluate the safety and immunogenicity of WRSs2 and WRSs3; two live oral candidate vaccines against Shigella sonnei.

Authors:

Secondary:

Volume:

Pagination:

Issue:

PMID:

DOI:

Keywords:

Abstract:

Go back to Resources

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 84
  • Page 85
  • Page 86
  • Page 87
  • Current page 88
  • Page 89
  • Page 90
  • Page 91
  • Page 92
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to
Emmes Group

Delivering Global Health
Impact Through People,
Science and Technology

Main navigation
  • Company
    • History
    • Leadership
    • Clients and Collaborators
    • By the Numbers
  • Capabilities
    • Emmes - CRO
    • Veridix - Tech & AI
  • Resources
    • Newsroom
    • Blog
  • Careers
  • Contact
    • Locations
    • Contact Us

Copyright ©, The Emmes Company, LLC

Footer
  • Cookie Policy
  • External Privacy Notice
  • FCOI
  • Emmes EU-U.S. Data Privacy Framework
  • Purchasing Terms and Conditions